Category Archives: 2018

Zytiga (Abiraterone) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

On February 8th, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga® (abiraterone acetate) in combination with prednisone for the treatment of patients with metastatic high-risk more »

Posted in 2018 | Leave a comment

Big Anxieties, Little Faith

As part of the Sermon on the Mount, Jesus spoke the following words from Matthew 6:25-30 about worry and anxiety, emotions and feelings most of us with prostate cancer can relate to. “Do not be anxious for your own life, more »

Posted in 2018 | Leave a comment

Apalutamide (ARN-509) Approved to Treat Non-Metastatic, Hormone-Resistant Prostate Cancer

On Feb. 14th, the U.S. Food and Drug Administration approved apalutamide (Erleada®, previously  called ARN-509) for the treatment of non-metastatic, castration (hormone)-resistant prostate cancer (CRPC). Apalutamide could be administered in a clinical setting wherein men who are being treated with more »

Posted in 2018 | Leave a comment

A Phase 3 Trial Shows that Xtandi Reduces the Risk of Metastasis in Hormone-Resistant Prostate Cancer

According to results just recently presented at the February 2018 Genitourinary Cancers Symposium in San Francisco, treatment with Xtandi® (enzalutamide) reduced the risk of metastasis or death in hormone-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond more »

Posted in 2018 | Leave a comment

Positive Early-Stage Study Results of ProstaVax, Another Prostate Cancer Vaccine.

OncBioMune’s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein (a hallmark of prostate cancer) with the cytokines — molecules produced by more »

Posted in 2018 | Leave a comment

Prostate Cancer Drugs Currently Approved or in Late-stage Clinical Trials.

At the time of this writing, there are thirteen (14) drugs currently approved by the Food and Drug Administration for the treatment of prostate cancer. There are others which are in various stages of clinical development or review.  A number of more »

Posted in 2018 | 1 Comment